Hikma Pharmaceuticals (LON:HIK) had its price target raised by Jefferies Group from GBX 1,045 ($14.06) to GBX 1,074 ($14.45) in a report published on Monday, December 4th. The firm currently has a hold rating on the stock.
A number of other equities research analysts have also recently commented on the stock. J P Morgan Chase & Co dropped their price objective on shares of Hikma Pharmaceuticals from GBX 1,500 ($20.19) to GBX 1,250 ($16.82) and set a neutral rating on the stock in a research note on Friday, October 6th. Numis Securities reiterated an add rating and set a GBX 1,560 ($21.00) target price on shares of Hikma Pharmaceuticals in a research report on Thursday, August 17th. Stifel Nicolaus lowered Hikma Pharmaceuticals to a hold rating and decreased their target price for the company from GBX 2,300 ($30.96) to GBX 1,320 ($17.77) in a research report on Tuesday, August 29th. Peel Hunt reiterated a hold rating and set a GBX 1,390 ($18.71) target price on shares of Hikma Pharmaceuticals in a research report on Wednesday, November 15th. Finally, Morgan Stanley reiterated an equal weight rating and set a GBX 1,100 ($14.80) target price on shares of Hikma Pharmaceuticals in a research report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of GBX 1,188.90 ($16.00).
Hikma Pharmaceuticals (LON HIK) opened at GBX 1,069 ($14.39) on Monday. Hikma Pharmaceuticals has a fifty-two week low of GBX 906.50 ($12.20) and a fifty-two week high of GBX 2,346 ($31.57).
About Hikma Pharmaceuticals
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.